Devicare secured EUR 1.6M in funding via Capital Cell.

Devicare, a Barcelona, Spain-based company developing digital therapeutic solutions (DTx) to improve in-home management of chronic diseases, secured funding of €1665180 ($1.9M).

The funding was raised via an equity crwodfunding campaign on Capital Cell which had an initial target of EUR 1.5M.

Devicare, founded in 2012 and led by CEO Rosendo Garganta,  is a technologically-driven company dedicated to developing digital therapeutic solutions (DTx) to improve in-home management of chronic diseases, combining diagnostics (Dx), monitoring (Mx) and nutritional therapies (Nx). These innovative solutions, such as Lit-Control in urology are created based on the concept of patient empowerment so that patients can actively participate in managing their own health.

The company holds 49 patents, a clinical programme with six studies in progress, strategic partnerships with renowned institutions such as the Puigvert Foundation and the University of the Balearic Islands’ Laboratory of Renal Lithiasis Research, and 20 international agreements with pharmaceutical companies in the field of urology. The company's headquarters is located in the UAB Research Park in Cerdanyola del Vallès (Barcelona).